BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 Study of BAL0891 as Monotherapy and in Combination With Chemotherapy or Tislelizumab in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and tolerability of increasing doses of BAL0891 in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia. An adaptive model-based design will be used to guide the dose escalation. Subject assignment to Substudy 1, 2, 3 and 4 will be finalized following approval from the investigator and sponsor.

The dose-expansion stage will be conducted with the RP2D to further evaluate the preliminary anti-tumor activity, safety, and tolerability in metastatic TNBC and GC.

Study Overview

• Status: Recruiting
• Conditions: Gastric Cancer; Advanced Solid Tumor; TNBC - Triple-Negative Breast Cancer; Leukemia Acute Myeloid Leukemia (AML)
• Intervention / Treatment: Drug: BAL0891; Combination product: Paclitaxel; Combination product: Tislelizumab

Detailed Description

Substudy 1 (monotherapy dose-escalation cohorts) This study will be initiated with enrollment into Substudy 1 and will estimate the safety, tolerability, PK, and PD of increasing doses of BAL0891 in patients with advanced solid tumors. The starting dose will be 5 mg based on the GLP (Good Laboratory Practice) toxicology studies. Dose escalation will comprise a dose range from a dose of 5 mg up to a maximum absolute dose of 480 mg, with eight nominal dose levels (DLs) of 5 / 10 / 20 / 40 / 80 / 160 / 320 / 480 mg. Intra-patient dose escalations are only allowed for patients enrolled in single-patient DL Cohorts 1.1, 1.2, and 1.3. From DL Cohort 1.4 onwards, the projected maximum dose-escalation factor will be two-fold; if the DL cohort investigates an increased dose, dosing of the patients within the cohort must be separated by at least 7 days. For cohorts in which doses are not increased (including backfill enrollment), patients may be enrolled concurrently.

BAL0891 will be administered intravenously (IV) on Day (D) 1 and D8 every 3 weeks (Q3W); for the schedule of assessments of Regimen A. Alternative 21-day or 28-day dosing regimens may be investigated; for the schedule of assessments of Regimens B-D.

Substudies 2 and 3 (dose-escalation cohorts for combination regimens) Enrollment into Substudies 2 and 3 may commence as early as first signs of expected target toxicity and/or efficacy with Regimen A (or an alternative monotherapy regimen) have been observed, or alternatively, once the MTD of BAL0891 monotherapy has been assessed. Patients enrolled into Substudies 2 and 3 will be treated with increasing doses of BAL0891 in combination with tislelizumab or paclitaxel, respectively, and dose escalation of both BAL0891 and tislelizumab/paclitaxel if required will use the same cumulative BLRM-EWOC model as Substudy 1. The starting dose of BAL0891 in combination with tislelizumab or paclitaxel will be a safe DL determined in Substudy 1 but not higher than approximately half the MTD. Backfill enrollment of up to a total of 30 additional patients for both substudies (who may be enrolled concurrently) may be used to better estimate the RP2D for each combination if required.

Substudy 4 (dose escalation cohort for monotherapy in r/r AML) Substudy 4 will evaluate BAL0891 monotherapy in patients with relapsed/refractory AML (r/r AML) using the same BLRM-EWOC model and study design described for Substudy 1. BAL0891 will be administered intravenously on Day 1 and Day 8 every three weeks (Regimen A; see Table 13 for schedule of assessments). Dose exploration will proceed until the highest planned dose level (DL) is determined to be safe and tolerable, or the MTD/RP2D is identified.

Each DL cohort will enroll three patients, with DLT observation required before advancing to the next DL. From DL2 onward, the projected maximum dose-escalation factor will be two-fold, with concurrent enrollment allowed for cohorts without dose increases. Backfill enrollment may be conducted to refine the RP2D and further characterize safety, efficacy and PD.

Part 2 : Dose expansion The commencement of the dose expansion stage will follow the determination of the RP2D achieved during the dose-escalation phase. This stage will consist of four cohorts, each comprising 24 patients who have previously undergone at least one systemic regimen for advanced or metastatic disease. Specifically, two cohorts will be allocated for TNBC, investigating BAL0891 both as a monotherapy and in combination with Paclitaxel. Additionally, two cohorts will be designated for GC, investigating the outcomes of BAL0891 as a monotherapy and in combination with Paclitaxel.

• Study Type: Interventional
• Enrollment (Estimated): 260
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: SillaJen Inc.; Phone Number: 02-368-2600; Email: patient_inquiry@sillajen.com

Study Locations

• South Korea
  • Seoul, South Korea
    • Recruiting
    • Samsung Medical Center
    • Contact: Samsung Medical Center
  • Seoul, South Korea
    • Recruiting
    • Seoul National University Hospital
    • Contact: Seoul National University Hospital
  • Seoul, South Korea
    • Recruiting
    • Asan Medical Center
    • Contact: Asan Medical Center
  • Seoul, South Korea, 06591
    • Recruiting
    • The Catholic University of Korea, Seoul St. Mary's Hospital
    • Contact: The Catholic University of Korea, Seoul St. Mary's Hospital
  • Seoul, South Korea
    • Recruiting
    • Severance Hospital, Yonsei University Health System
    • Contact: Severance Hospital, Yonsei University Health System
  • Seoul, South Korea
    • Recruiting
    • Korean University Anam Hospital
    • Contact: Korean University Anam Hospital
• United States
  • Connecticut
    • New Haven, Connecticut, United States, 06510
      • Recruiting
      • Yale New Haven Hospital
      • Contact: Yale New Haven Hospital
  • Florida
    • Coral Gables, Florida, United States, 33146
      • Recruiting
      • University of Miami Health System
      • Contact: University of Miami Health System
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Recruiting
      • Winship Cancer Institute / Emory University
      • Contact: Winship Cancer Institute / Emory University
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • Recruiting
      • University of Michigan
      • Contact: University of Michigan
  • New York
    • New York, New York, United States, 10021
      • Recruiting
      • Weill Cornell Medicine- NewYork-Presbyterian Hospital
      • Contact: Weill Cornell Medicine- NewYork-Presbyterian Hospital
    • The Bronx, New York, United States, 10461
      • Recruiting
      • Montefiore Medical Center
      • Contact: Montefiore Medical Center
  • Oregon
    • Portland, Oregon, United States, 97239
      • Active, not recruiting
      • OHSU Knight Cancer Institute
  • Texas
    • Dallas, Texas, United States, 75230
      • Withdrawn
      • Mary Crowley Cancer Research
    • Houston, Texas, United States, 77030
      • Recruiting
      • The University of Texas MD Anderson Cancer Center
      • Contact: The University of Texas MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

1.1. Inclusion criteria: Substudy 1, 2, 3 and Dose expansion Each patient must meet all the following inclusion criteria.

1. Informed consent signed by the patient prior to any study-related procedure indicating that they understand the purpose of, and procedures required for, the study, and are willing to participate in the study.
2. Male or female aged ≥18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening.

3. Patients with incurable advanced/metastatic solid tumor disease refractory to or intolerant of existing therapy known to provide clinical benefit for their condition.

   Note: Patients with non-CNS tumors participating during dose escalation may have inactive CNS metastasis, defined as 4 weeks after either brain metastasis resection or radiation, and a) all residual neurological symptoms resolved to grade ≤ 2; b) on stable doses of dexamethasone, if applicable; and c) follow-up imaging shows no new lesions appearing.

4. Patients enrolled in Dose Expansion only

   • TNBC cohorts i. Must have histologically confirmed breast adenocarcinoma that is unresectable, loco-regional, or metastatic.

   ii. Must have source data documented pathologically confirmed triple negative breast cancer, defined as both of the following.

   1. Estrogen receptor (ER) and progesterone receptor (PgR) negative: <1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls)

   2. Human epidermal growth factor receptor 2 (HER2) negative as per American Society of Clinical Oncology/College of American Pathologists guidelines

      • IHC 0 or 1 fluorescence in situ hybridization (FISH) negative (or equivalent negative test)
      • Patients with IHC 2 must have a negative by FISH (or equivalent negative test) iii. Patients with a history of different breast cancer phenotypes (i.e., ER/PgR/HER2 Positive) must obtain pathological confirmation of triple-negative disease in at least one of the current sites of metastasis.

   iv. Must have progression on or after therapy containing anthracycline and/or a taxane. Subjects must have received anthracycline and/or a taxane based regimen or other chemotherapy / targeted therapy regimen if anthracycline or taxane was contraindicated or another available approved targeted agent was contraindicated. At time of enrolment, patients must have progressed on, be intolerant of, or be ineligible for, all available standard of care therapies with proven benefit.

   • GC cohort i. Must have a histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.

   ii. Must have progression on or after therapy containing platinum/fluoropyrimidine. Subjects must have received platinum-based chemotherapy or other chemotherapy regimen if platinum-based chemotherapy was contraindicated or another available approved targeted agent unless the targeted agent was contraindicated. At time of enrolment, patients must have progressed on, be intolerant of, or be ineligible for, all available standard of care therapies with proven benefit.

   iii. Documentation of HER2/neu status. Patients who are HER2/neu-positive must be treated with a HER2/neu inhibitor, and subjects should have progressed on or be intolerant to the targeted therapy or subjects must have received other chemotherapy regimen if HER2/neu inhibitor was contraindicated or another available approved targeted agent unless the targeted agent was contraindicated. At time of enrolment, patients must have progressed on, be intolerant of, or be ineligible for, all available standard of care therapies with proven benefit.

   iv. Subjects must/should have received no more than 3 lines of prior therapy for the advanced disease (if a subject progressed within 6 months of completing adjuvant therapy, this would count as a prior line of therapy).

5. For patients enrolled in Substudy 3 or cohort 3 and 4, if a taxane (i.e., paclitaxel or docetaxel) was administered as part of the previous regimen, PD must have occurred > 12 months from the end of the previous treatment. (Patients who received a taxane in previous treatments without reaching PD may enroll without the 12-month waiting period.)
6. Patients enrolled in Dose Expansion only, patient must have undergone a minimum of 1 prior systemic regimen for advanced or metastatic disease. (Korea only, patients must have received the second line standard of care treatment as per the regulations of the respective country. Patients who are unsuitable to receive the standard of care second line treatment will be eligible for enrollment)
7. Eastern Cooperative Oncology Group performance status (ECOG PS) 0or-1
8. For patients enrolled from DL1.4 of Substudy 1 onwards and for all patients in Substudies 2 and 3 and all four dose expansion cohorts, measurable tumor disease per Response Evaluation Criteria in Solid Tumors 1.1 criteria (RECIST 1.1), i.e., a minimum of one target lesion.

9. Adequate organ functions as indicated by the following Screening visit local laboratory values:

   1. Hemoglobin ≥ 9 g/dL (criterion must be met without erythropoietin dependency and without packed red blood cell transfusion within the last 4 weeks)
   2. ANC ≥ 2.0 × 109/L; criterion must be met without growth factor (e.g., G-CSF, GM CSF, etc.) administration within the last 2 weeks
   3. Platelets ≥ 100 × 109/L
   4. Total bilirubin ≤ 1.5 × ULN
   5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) baseline levels ≤ 1.5 × ULN, with the option for AST/ALT ≤ 3.0 × ULN, or ≤ 5.0 × ULN for patients with liver metastasis, upon accumulating evidence for the absence of liver toxicity in biologically active DLs
   6. Albumin ≥ 2.8 g/dL
   7. CLCR ≥ 50 mL/min (as calculated by the Cockcroft-Gault formula), or eGFR ≥ 50 mL/min/1.73 m² (MDRD equation or CKD-EPI equation)
   8. For women of childbearing potential, negative serum human chorionic gonadotropin (hCG)
10. Men/women of child-producing/bearing potential must agree to: avoid impregnating a partner or becoming pregnant, respectively, during the study, and for at least 6 months after the last dose of either investigational drug, and comply with the contraception requirements.

1.2. Inclusion criteria: Substudy 4 Each patient must meet all the following inclusion criteria.

1. Informed consent signed by the patient prior to any study-related procedure indicating that they understand the purpose of, and procedures required for, the study, and are willing to participate in the study.
2. Male or female aged ≥18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening.
3. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
4. Estimated life expectancy of at least 8 weeks

5. AML either de novo or secondary as any subtype diagnosed according to the WHO 2022 classification system [except acute promyelocytic leukemia (APL)] who either:

   Relapse/refractory (R/R) acute myeloid leukemia (AML) defined as those who have also failed or are not appropriate for any approved standard-of-care (SOC) therapies, or hematopoietic stem cell transplant (HSCT) with reappearance of ≥ 5% blasts in the bone marrow.

6. Relapsed AML is defined as having 5% or more leukemic blasts in the bone marrow, reappearance of leukemic blasts in peripheral blood (in at least two peripheral blood samples taken at least one week apart), or the development of new extramedullary disease.

7. WBC, peripheral blood leukocyte count≤ 25,000/µL and blast count ≤ 25,000/µL prior to initiation of therapy

   1. Hydroxyurea is allowed during screening and prior to day 1 of study treatment to keep the blast count ≤25,000/µL; hydroxyurea is to be ceased 24 hours prior to study therapy.
   2. Hydroxyurea may be used for up to 28 days in the initial treatment cycle if needed, to keep the white blood cell (WBC) count ≤25,000/µL. However, no other anti-leukemic treatments, apart from the study drug, are allowed during this period.
   3. Leukapheresis is allowed to maintain blast count ≤25,000/µL

8. Adequate organ functions as indicated by the following Screening visit local laboratory values:

   1. CLCR ≥ 60 mL/min (as calculated by the Cockcroft-Gault formula), or eGFR ≥ 60 mL/min/1.73 m² (MDRD equation or CKD-EPI equation)
   2. Total bilirubin ≤ 1.5 × ULN (unless considered due to leukemic organ involvement), or, Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
   3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) baseline levels ≤ 3.0 × ULN
   4. Albumin ≥ 2.5 g/dL
   5. International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
   6. Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
9. Men/women of child-producing/bearing potential must agree to: avoid impregnating a partner or becoming pregnant, respectively, during the study, and for at least 6 months after the last dose of either investigational drug, and comply with the contraception requirements.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part 1: Substudy 1, Dose-escalation substudy of BAL0891 monotherapy; Increasing doses of BAL0891 will be administered IV on D1 and D8 Q3W (Regimen A). BAL0891 will be investigated in a dose range of 5-480 mg with Regimen A. Optionally, and based on cumulative safety, PK, and PD data, BAL0891 may be administered on D1 Q3W (Regimen B), D1 and D15 Q4W (Regimen C), or on D1, D8, and D15 Q4W (Regimen D).	Drug: BAL0891; BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1); Other Names: TTK-CS-101
Experimental: Part 1: Substudy 3, Dose-escalation substudy of BAL0891 in combination with paclitaxel; Paclitaxel will be dosed at 70 mg/m2 on D1, D8, and D15 Q4W, with an option to use 80 mg/m2 (either instead of, or after exploring, 70 mg/m2) if the cumulative data collected at that time support a higher dose of paclitaxel.	Drug: BAL0891; BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1); Other Names: TTK-CS-101; Combination product: Paclitaxel; Paclitaxel is a natural product with antitumor activity; Other Names: Taxol
Experimental: Part 2 : Dose expansion, cohorts 1 TNBC (BAL0891 monotherapy); BAL0891 will be administered intravenously on D1 and D8, Q3W for cohorts 1. The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 1 will utilize the RP2D established in substudy 1 of the dose escalation phase.	Drug: BAL0891; BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1); Other Names: TTK-CS-101
Experimental: Part 2 : Dose expansion, cohorts 2 GC (BAL0891 monotherapy); BAL0891 will be administered intravenously on D1 and D8, Q3W for cohorts 2. The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 2 will utilize the RP2D established in substudy 1 of the dose escalation phase.	Drug: BAL0891; BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1); Other Names: TTK-CS-101
Experimental: Part 2 : Dose expansion, cohorts 3 TNBC (BAL0891 + Paclitaxel); BAL0891 will be administered intravenously on D1 and D15, Q4W for cohorts 3 . The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 3 will utilize the RP2D established in substudy 3 of the dose escalation phase.	Drug: BAL0891; BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1); Other Names: TTK-CS-101; Combination product: Paclitaxel; Paclitaxel is a natural product with antitumor activity; Other Names: Taxol
Experimental: Part 2 : Dose expansion, cohorts 4 GC (BAL0891 + Paclitaxel); BAL0891 will be administered intravenously on D1 and D15, Q4W for cohorts 4. The investigation will focus on the RP2D determined during the dose escalation phase of the study. Specifically, cohorts 4 will utilize the RP2D established in substudy 3 of the dose escalation phase.	Drug: BAL0891; BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1); Other Names: TTK-CS-101; Combination product: Paclitaxel; Paclitaxel is a natural product with antitumor activity; Other Names: Taxol
Experimental: Part 1: Substudy 4, Dose-escalation substudy of BAL0891 monotherapy in r/r AML; BAL0891 will be administered intravenously on Day 1 and Day 8 every three weeks (Regimen A). Dose exploration will proceed until the highest planned dose level (DL) is determined to be safe and tolerable, or the MTD/RP2D is identified.	Drug: BAL0891; BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1); Other Names: TTK-CS-101
Experimental: Part 1: Substudy 2, Dose-escalation substudy of BAL0891 in combination with tislelizumab; Increasing doses of BAL0891 will be administrated IV on D1 and D15 with tislelizumab administration on D8 Q3W. The starting dose of BAL0891 for combination will be at approximately 50% of the BAL0891 monotherapy MTD determined in Substudy 1 and tislelizumab dose will be 200mg IV.	Drug: BAL0891; BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1); Other Names: TTK-CS-101; Combination product: Tislelizumab; Tislelizumab a humanized IgG4 anti-PD-1 monoclonal antibody

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1: Number of Participants With Adverse Events as a Measure of Safety and Tolerability	Safety is collected through summaries of AE(Adverse Event)s, safety laboratory evaluations, PK evaluations, physical examinations, vital signs, and ECGs using CTCAE v5.0.	After first dose, up to 2 years
Part 1: Number of Participants With the DLT (Dose-limiting toxicity)s as a Measure of maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D)	DLTs are collected through BLRM-EWOC.	After first dose and within 7 days of End of Treatment, up to 2 years
Part 2: Overall response rate (ORR) for all subjects	The proportion of patients with confirmed complete response (CR) or partial response (PR) by RECIST 1.1/iRECIST (substudy 2 only) during the dose expansion phase.	Every 3 months (±14 days) after first dose, up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1: Pharmacokinetics (PK) parameters for all subjects	The area under the plasma concentration-time curve (AUC) by PK Sampling	Within 7 days of End of Treatment, up to 2 years
Part 1: Absolute neutrophil count (ANC) for all subjects	Duration of neutropenia by PD Sampling	Within 7 days of End of Treatment, up to 2 years
Part 1, 2: Disease control rate (DCR) for all subjects	The proportion of patients with confirmed CR, PR or stable disease (SD) by RECIST 1.1	Within 7 days of End of Treatment, up to 2 years
Part 1, 2: Progression-free survival (PFS) for all subjects	Measured from patient enrollment to disease progression date	Within 7 days of End of Treatment, up to 2 years
Part 1, 2: Overall survival (OS) for all subjects	Measured from from patient enrollment to time of death	Within 7 days of End of Treatment, up to 2 years
Part 1, 2: Overall response rate (ORR) for all subjects	The proportion of patients with confirmed complete response (CR) or partial response (PR) by RECIST 1.1	Every 3 months (±14 days) after first dose, up to 2 years
Part 2: Safety evaluations for all subjects	Safety evaluations is focusing on key clinical evlauations such treatment-emergent adverse events (TEAE) using CTCAE v5.0.	After first dose, up to 2 years
Part 1: Efficacy Endpoints CR + CRh Rate (Substudy 4)	Proportion of patients achieving Complete Remission (CR) or CR with partial hematologic recovery (CRh) per European LeukemiaNet (ELN) 2022 guidelines.	Up to 2 years
Part 1: Efficacy Endpoints Duration of Remission (DoR) (Substudy 4)	Time from first documented CR/CRh until relapse or death.	Up to 2 years
Part 1: Efficacy Endpoints Transfusion Independence (TI) (Substudy 4)	Proportion of patients achieving red blood cell (RBC) and platelet transfusion independence for ≥56 consecutive days.	Up to 2 years
Part 1: Efficacy Endpoints CR/CRh without Measurable Residual Disease (MRD) (Substudy 4)	Proportion of patients achieving CR/CRh and MRD negativity.	Up to 2 years
Part 1: Efficacy Endpoints Composite Complete Remission (CRc) Rate (Substudy 4)	Proportion of patients achieving CR, CRh, or CR with incomplete hematologic recovery (CRi).	Up to 2 years
Part 1: Efficacy Endpoints Overall Response Rate (ORR) (Substudy 4)	Proportion of patients achieving CR, CRh, CRi, or Partial Remission (PR).	Up to 2 years
Part 1: Efficacy Endpoints Overall Survival (OS) (Substudy 4)	Time from first dose of BAL0891 to death from any cause.	Up to 2 years
Part 1: Efficacy Endpoints Event-Free Survival (EFS) (Substudy 4)	Time from first dose of BAL0891 to disease progression, relapse, or death.	Up to 2 years
Part 1: Efficacy Endpoints Time to Response (TTR) (Substudy 4)	Time from first dose of BAL0891 to first documented response.	Up to 2 years
Part 1: QTcF Interval Analysis	Analysis of QTcF interval data collected during BAL0891 monotherapy and the relationship between BAL0891 exposure and QTcF interval prolongation.	From first dose to 30 days post last dose

Collaborators and Investigators

• Sponsor: SillaJen, Inc.
• Investigators: Study Director: SillaJen Inc., SillaJen, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): December 14, 2022
• Primary Completion (Estimated): December 24, 2026
• Study Completion (Estimated): December 24, 2026

Study Registration Dates

• First Submitted: January 29, 2023
• First Submitted That Met QC Criteria: March 2, 2023
• First Posted (Actual): March 15, 2023

Study Record Updates

• Last Update Posted (Actual): March 27, 2026
• Last Update Submitted That Met QC Criteria: March 23, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: carcinoma; paclitaxel; tislelizumab; BAL0891
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Hematologic Diseases; Neoplasms, Glandular and Epithelial; Skin Diseases; Breast Diseases; Leukemia, Myeloid; Leukemia; Breast Neoplasms; Skin and Connective Tissue Diseases; Hemic and Lymphatic Diseases; Stomach Neoplasms; Carcinoma; Leukemia, Myeloid, Acute; Triple Negative Breast Neoplasms; Organic Chemicals; Hydrocarbons; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Terpenes; Taxoids; Cyclodecanes; Diterpenes; Paclitaxel; tislelizumab
• Other Study ID Numbers: TTK-CS-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No